[Taking metabolic pathways into consideration. Approved drug against problematic interactions ].
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000097:blood; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D051544:Cytochrome P-450 CYP3A / Q000097:blood; D004347:Drug Interactions; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D000077402:Pantoprazole; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000493:pharmacokinetics
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D000077144:Clopidogrel; D000077402:Pantoprazole; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D013988:Ticlopidine